Citations

Clear

5 citation(s) found for "Zurawski, V R".

A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
Sharara, Sima L. , Diaz, Lorena, Asempa, Tomefa E, Martinez, Jose R W, Canales, Nicolas, Bergman, Yehudit , Murphy, Shannon G. , Karaba, Sara M. , Clark, Andrew E. , Zurawski, Daniel V, Cosgrove, Sara E, Simner, Patricia J, Munita, José M. , Tamma, Pranita D. , Tamma, Pranita D , Clark, Andrew E. , Karaba, Sara M , Bergman, Yehudit , Munita, Jose M , Sharara, Sima L. , Díaz, Lorena , Asempa, Tomefa E. , Canales, Nicolás, Murphy, Shannon G. , Zurawski, Daniel V. , Cosgrove, Sara E. , Simner, Patricia J.

Mayo Clinic

Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag436 | PMID 42442753 Get It

Abstract We report an eightfold increase in sulbactam-durlobactam MICs in a carbapenem-resistant Acinetobacter baumannii cerebrospinal fluid isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.
Cancer Cells Promote Immune Regulatory Function of Macrophages by Upregulating Scavenger Receptor MARCO Expression
Wiest, Matthew, Zhang, Wei , Halder, Kuntal, Zurawski, Sandy, Zurawski, Gérard , Joo, HyeMee , Oh, SangKon, Gu, Chao , Gu, Chao

Mayo Clinic

The Journal of Immunology | May 22, 2023 | Volume: 211 | Issue: 1 | Pages: 57-70

10.4049/jimmunol.2300029 | PMID 37212598 Get It

Abstract Expression of macrophage receptor with collagenous structure (MARCO) by tumor-associated macrophages is associated with poor prognosis of multiple types of cancer. In this article, we report that cancer cells (e.g., breast cancer and glioblastoma cell lines) can upregulate surface MARCO expression on human macrophages not only via IL-6–induced STAT3 activation but also via sphingosine-1-phosphate receptor (S1PR)-mediated IL-6 and IL-10 expression followed by STAT3 activation. We further found that MARCO ligation induces activation of the MEK/ERK/p90RSK/CREB signaling cascade, leading to IL-10 expression followed by STAT3-dependent PD-L1 upregulation. Such MARCO-induced macrophage polarization is accompanied by increased expression of PPARG, IRF4, IDO1, CCL17, and CCL22. Ligation of surface MARCO can thus result in decreased T cell responses mainly by reduction of their proliferation. Taken together, cancer cell–induced MARCO expression and its intrinsic regulatory function within macrophages are, to our knowledge, new aspects of cancer immune evasion mechanisms that need to be further studied in the future.
Signaling Cascade through DC-ASGPR Induces Transcriptionally Active CREB for IL-10 Induction and Immune Regulation
Wang, Lei , Zurawski, Sandra , Oh, SangKon , Gu, Chao , Wang, Lei , Gu, Chao

Mayo Clinic

The Journal of Immunology | June 7, 2019 | Volume: 203 | Issue: 2 | Pages: 389-399

10.4049/jimmunol.1900289 | PMID 31175164 Get It

Abstract The types and magnitude of Ag-specific immune responses can be determined by the functional plasticity of dendritic cells (DCs). However, how DCs display functional plasticity and control host immune responses have not been fully understood. In this study, we report that ligation of DC–asialoglycoprotein receptor (DC-ASGPR), a C-type lectin receptor (CLR) expressed on human DCs, resulted in rapid activation of Syk, followed by PLCγ2 and PKCδ engagements. However, different from other Syk-coupled CLRs, including Dectin-1, signaling cascade through DC-ASGPR did not trigger NF-κB activation. Instead, it selectively activated MAPK ERK1/2 and JNK. Rapid and prolonged phosphorylation of ERK1/2 led to sequential activation of p90RSK and CREB, which consequently bound to IL10 promoter and initiated cytokine expression. In addition, DC-ASGPR ligation activated Akt, which differentially regulated the activities of GSK-3α/β and β-catenin and further contributed to IL-10 expression. Our observations demonstrate that DC-ASGPR induces IL-10 expression via an intrinsic signaling pathway, which provides a molecular explanation for DC-ASGPR–mediated programing of DCs to control host immune responses.
Central Roles of OX40L–OX40 Interaction in the Induction and Progression of Human T Cell–Driven Acute Graft-versus-Host Disease
Tripathi, Trivendra , Yin, Wenjie , Xue, Yaming, Zurawski, Sandra , Fujita, Haruyuki, Hanabuchi, Shino , Oh, SangKon, Joo, HyeMee , Yin, Wenjie , Liu, Yong-Jun

Mayo Clinic

ImmunoHorizons | March 21, 2019 | Volume: 3 | Issue: 3 | Pages: 110-120

10.4049/immunohorizons.1900001 | PMID 31240276 Get It

Abstract Graft-versus-host disease (GVHD) is one of the major obstacles for the success of allogeneic hematopoietic stem cell transplantation. In this article, we report that the interaction between OX40L and OX40 is of critical importance for both induction and progression of acute GVHD (aGVHD) driven by human T cells. Anti-human OX40L mAb (hOX40L) treatment could thus effectively reduce the disease severity in a xenogeneic-aGVHD model in both preventative and therapeutic modes. Mechanistically, blocking OX40L–OX40 interaction with an anti-hOX40L reduces infiltration of human T cells in target organs, including liver, gut, lung, and skin. It also decreases IL-21– and TNF-producing T cell responses while promoting regulatory T cell responses without compromising the cytolytic activity of CD8+ T cells. Single blockade of hOX40L was thus more effective than dual blockade of IL-21 and TNF in reducing the severity of aGVHD as well as mortality. Data from this study indicate that OX40L–OX40 interactions play a central role in the pathogenesis of aGVHD induced by human T cells. Therapeutic strategies that can efficiently interrupt OX40L–OX40 interaction in patients might have potential to provide patients with an improved clinical benefit.
Coordinate elevation of serum markers in ovarian cancer but not in benign disease
Bast, Robert C. , Knauf, S., Epenetos, A A, Dhokia, B, Daly, L., Tanner, M., Soper, John T. , Creasman, William T., Gall, Stanley A., Knapp, Robert C., Zurawski, V R, Schlom, J, Kufe, D, Ritts, Roy E., Bast, Robert C

Mayo Clinic

Cancer | June 27, 2006 | Volume: 68 | Issue: 8 | Pages: 1758-1763

10.1002/1097-0142(19911015)68:8<1758::aid-cncr2820680819>3.0.co;2-# | PMID 1913520 Get It